Policy & Regulation
SoftOx doses first patient in SIS-03 proof-of-concept trial
11 August 2026 - Clinical-stage pharmaceutical company SoftOx Solutions AS (Euronext Growth Oslo:SOFTX) announced on Tuesday that the first patient has been dosed in the proof-of-concept phase of its ...
BSF secures exclusive global commercialisation partnership for ETSYL
11 August 2026 - BSF Enterprise plc (LON:BSFA), a biotechnology company focused on tissue engineering, lab-grown materials and bioactive solutions, said on Tuesday that it has signed Heads of Terms wi...
Aureka Biotechnologies raises USD100m to build biological world model for drug discovery
11 August 2026 - Aureka Biotechnologies, an AI-native TechBio company, announced on Monday the close of a USD100m Series B financing.Granite Asia funded the first tranche exclusively, and a prominent ...
Kodiak Sciences enrols first patients in KSI-501 Phase 3 ALTO trial in patients with diabetic macular oedema
11 August 2026 - Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, announced on Monday that the first patients have been enrolled in the global Phase 3 ALTO trial...
AbCellera reports positive Phase 2 results for menopause treatment ABCL635
10 August 2026 - Biotechnology company AbCellera (Nasdaq: ABCL) on Monday reported positive topline Phase 2 results for ABCL635, an investigational neurokinin 3 receptor antagonist antibody being deve...
Bristol Myers Squibb to invest USD2.3bn in Houston manufacturing campus
10 August 2026 - Biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE:BMY) announced on Monday that it has selected Houston, Texas, for a new multi-modal manufacturing campus representing an inv...